Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease GASTROENTEROLOGY CLINICS OF NORTH AMERICA Sonu, I., Lin, M. V., Blonski, W., Lichtenstein, G. R. 2010; 39 (3): 559-?


Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.

View details for DOI 10.1016/j.gtc.2010.08.011

View details for Web of Science ID 000284291900011

View details for PubMedID 20951918